Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Study results from Princess Margaret Hospital broaden understanding of adverse drug reactions
May 13th, 2008
" A tool that quantifies the risk of treatment-related toxicity based on individual patient characteristics can augment the informed consent process and safety monitoring in the setting of phase II cancer treatment trials of molecularly targeted agents (MTAs). A regression model was constructed to predict the risk of a serious adverse event (SAE) with an MTA and presented as a nomogram," researchers in Toronto, Canada report. "Estimation of risk can be performed by integrating risk estimates from the nomogram and from a reference or average patient. Internal validation was performed using bootstrapping techniques. A total of 578 patients were treated with one of 14...
Source: Cancer Weekly (2008-05-13)
|
